Medtronic has announced the launch of an app-based research study that is aimed at addressing a number of unanswered questions based around atrial fibrillation (AF) burden and its impact on patient outcomes and quality of life.
According to Medtronic, the study will make use of data collected from the LINQ family of insertable cardiac monitors (ICMs). The first patients in the DEFINE AFib study were enrolled at Duke University Medical Center and the Florida Electrophysiology Associates in Atlantis, Florida.
Commenting on the study, Jonathan Paul Piccini, director of cardiac electrophysiology and associate professor of medicine at Duke University School of Medicine and chair of the DEFINE AFib Steering Committee, stated that he hoped the study would provide the tools to enable patients to benefit from a tailored approach to AF management.
"When it comes to managing atrial fibrillation, there is not a ‘one-size-fits-all’ approach, and the hope is that DEFINE AFib may give us the tools to help personalize AF management based on a patient’s individual health profile and physiology," he said. "DEFINE AF will harness the power of digital health to make fundamental discoveries about how we can manage atrial fibrillation better in each and every one of our patients."